Speaker Profile

M.D., VP of Clinical Development, GRAIL, Inc.

Anne-Renee Hartman is the Vice President of Clinical Development at GRAIL, Inc. where she is responsible for the design and execution of clinical programs to discover and validate cell-free nucleic acid technology for early detection of cancer. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, Inc. At Myriad, Anne-Renee led the development of several commercialized diagnostics in oncology, including hereditary cancer testing, companion diagnostics for PARP therapy, and diagnostic and prognostic assays for melanoma, lung, and prostate cancer. Anne-Renee was previously an Assistant Professor of Medicine at The Dana-Farber Cancer Institute, specializing in breast cancer genetics. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a Bachelor’s degree in Molecular Biology from Princeton University, an M.D. from the University of Michigan, and completed her residency in Internal Medicine at the University of Chicago.

Session Abstract – PMWC 2018 Silicon Valley

Session Synopsis: This panel will focus on how the use of novel approaches such as liquid biopsies and technologies such as NGS can be integrated in personalized medicine to improve patient management. We will discuss what it will take for the most recent developments to be incorporated in routine clinical care.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.